Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nanjing Univ. of Chinese Medicine PKM2 compound B4
- Development stage
- Preclinical
- Lead developer
- Nanjing University of Chinese Medicine
01
Overview
Nanjing Univ. of Chinese Medicine PKM2 compound B4: sourced facts only. name: "Thus, B4 is confirmed as a potent PKM2 activator, and has the potential to develop as a novel anti-UC agent." [PMID:38718622]; target: "Thus, B4 is confirmed as a potent PKM2 activator, and has the potential to develop as a novel anti-UC agent." [PMID:38718622]; developer: "Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China." [PMID:38718622]; stage: "Finally, B4 can notably ameliorate the symptoms of dextran sulfate sodium (DSS)-induced colitis in mouse model in vivo." [PMID:38718622]
02
Targets
PKM2 (Pyruvate kinase M2 isoform)
Beyond the preview
Go deeper on Nanjing Univ. of Chinese Medicine PKM2 compound B4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing Univ. of Chinese Medicine PKM2 compound B4.